{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT00113893: Phase 2 Interventional Completed Bone Marrow Diseases
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Talmapimod is a p38 MAPK kinase inhibitor that inhibits p38 alpha with IC50 value of 9 nM which is 10-times lower then IC50 for p38 beta. Talmapimod was under clinical development for the treatment of Myelodysplastic Syndromes, Multiple Myeloma and Rheumatoid Arthritis (phase II), however, it seems to be discontinued as no longer presents in Janssen's pipeline.
Status:
Investigational
Source:
INN:zelebrudomide [INN]
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Darglitazone is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and is used in the treatment of metabolic disorders such as type II diabetes. Darglitazone sodium had been in phase I clinical trials by Pfizer for the treatment of type 2 diabetes. However, this study has been discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cormethasone is a topical antiinflammatory corticosteroid discovered by Du Pont.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Clometherone is an investigational derivative of progesterone, possessing antiestrogen and antiandrogen activities. It was developed by Eli Lilly in the 1960s and was found to significantly suppress the estrone induced uterine hypertrophy in mice at an oral or subcutaneous dose of 10ug. In a clinical trial, administration of clometherone to adult males lead to a slight increase in sebum production.
Status:
Investigational
Source:
NCT00315250: Phase 2 Interventional Completed Parkinson's Disease
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iometopane I-123 is a tropane derivative labeled with iodine-123 that was being developed by MGI GP (MGI Pharma) as an injectable Single-photon emission computed tomography (SPECT) imaging agent. The ability of iometopane to bind to the dopamine transporter on presynaptic dopaminergic nerve terminal in the striatum has been used to differentiate the uptake of the agent by the neurons in the striatum in patients with a Parkinsonian disorder from patients without a Parkinsonian disorder with high sensitivity and specificity. The diminished uptake of iometopane in the striatum on the SPECT images of patients with a Parkinsonian disorder can be applied to assess both disease trait and disease state (severity) reflected by the severity of the brain dopamine neuron loss. Unfortunately Phase III clinical trials and further development of iometopane was discontinued due to the inability to contract a suitable manufacturer for the clinical and commercial supply of iometopane on acceptable conditions in the US. Currently, Iometopane is mainly used in scientific research into the dopamine reuptake transporter.
Status:
Investigational
Source:
INN:zosurabalpin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (RACEMIC)
Talmetacin is a cyclo-oxygenase inhibitor that was studied as an analgesic and antipyretic agent. This drug was studied in Argentina in patients with rheumatic disorders. However, further development of talmetacin is not available.
Status:
Investigational
Source:
NCT03756103: Phase 2 Interventional Completed Hypertension,Essential
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ACHIRAL)
Prinoxodan (also known as RGW2938) is a benzodiazinone derivative patented by Rorer International (Overseas), Inc as inotropic agents, useful in treating congestive heart failure. Prinoxodan administered intravenously (i.v.) to anesthetized dogs increased contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. A single oral dose of Prinoxodan administered to conscious chronically instrumented dogs produced a marked and sustained increase in contractility 15-240 min after treatment.
